share_log

Needham Maintains Buy on Esperion Therapeutics, Lowers Price Target to $8

Benzinga ·  Nov 7, 2023 15:29

Needham analyst Serge Belanger maintains Esperion Therapeutics (NASDAQ:ESPR) with a Buy and lowers the price target from $9 to $8.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment